Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Multaq REMS May Be Revamped As Label Adds New Risks

Dec 19 2011

• By Emily Hayes

Related Content

Sometimes It Takes Two NDAs For One Approval: Multaq Odyssey Shows FDA In Search Of Reassurance In Tricky Antiarrhythmic Field

Mar 01 2010

Where A REMS Didn't Help: Sanofi Must Deal With Liver Injuries With Multaq

Jan 14 2011

Multaq Panel Resolves Mortality Concerns, Looks At Restricted Claims

Mar 23 2009

EMA's Restriction Of Multaq Indication Could Spell Death Knell For The Drug In Europe

Sep 23 2011

Sanofi Halts Multaq Trial Early Due To Cardiac Events

Jul 07 2011

FDA Approves Multaq With REMS, Without Mortality Claim

Jul 04 2009

Related Companies

Sanofi

Boehringer Ingelheim GmbH

Additional Topics

Regulation Safety BioPharmaceutical

More from Drug Safety

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window